The global plant molecular farming market is entering a transformative growth phase as healthcare and agriculture sectors increasingly adopt plant-based expression systems for safer, faster, and more cost-effective drug and vaccine development. According to Precedence Research, the market is projected to expand significantly between 2025 and 2034, propelled by the rising demand for recombinant proteins, vaccines, therapeutic biologics, and nutraceuticals produced from plants. With North America currently holding a 35% market share in 2024 and Asia Pacific emerging as the fastest-growing region, industry stakeholders are witnessing a pivotal shift in how biologics are developed and scaled.
Quick Insights
-
Market Leadership: North America held 35% share in 2024.
-
Fastest-Growing Region: Asia Pacific, supported by government funding and healthcare expansion.
-
Top Product Segment: Therapeutic proteins, accounting for 45% share in 2024.
-
Fastest-Growing Product: Vaccines, driven by pandemic preparedness and affordability needs.
-
Dominant Plant System: Tobacco-based expression systems with 40% market share in 2024.
-
Fastest-Growing Expression Platform: Leafy crops like spinach and lettuce.
-
Production Leadership: Transient expression methods contributed 50% share in 2024.
-
End-User Leader: Pharmaceutical and biotechnology companies with 55% market share.
-
Fastest-Growing End User: Contract development and manufacturing organizations (CDMOs).
This Report is Readily Available for Immediate Delivery | Download the Sample Pages of this Report@ https://www.precedenceresearch.com/sample/6723
Market Drivers: Why is plant molecular farming gaining momentum?
The market’s growth is underpinned by several structural drivers. Rising demand for biopharmaceuticals, including vaccines, monoclonal antibodies, and therapeutic proteins, is steering adoption of plant-based systems. Unlike mammalian cell cultures, plant molecular farming offers greater safety, reduced contamination risk, scalability, and lower production costs.
Technological advancements, particularly transient expression systems, CRISPR gene editing, and AI-enabled optimization, are enhancing protein yields, shortening R&D timelines, and making large-scale manufacturing economically viable. Moreover, pandemic preparedness initiatives and sustainability imperatives are pushing governments and companies alike to embrace these systems for rapid-response vaccine production.
Industry Opportunities and Trends: What’s next for plant molecular farming?
-
Vaccine Expansion: The ability to rapidly scale plant-based vaccines during health crises creates immense opportunities.
-
Therapeutic Protein Development: Plants are being used to develop complex proteins and monoclonal antibodies, creating new revenue streams.
-
AI Integration: Artificial intelligence is revolutionizing plant molecular farming by predicting gene edits, improving growth conditions, and accelerating protein optimization.
-
Edible Biologics: Leafy crops producing edible vaccines could redefine accessibility in low- and middle-income countries.
-
Sustainability Edge: Investors are drawn to ESG-friendly production platforms that minimize waste and eliminate animal-based inputs.
Expert Perspective
“Plant molecular farming represents the convergence of biotechnology, agriculture, and artificial intelligence. We are seeing unprecedented opportunities in scalable vaccine production and cost-efficient therapeutic proteins. As governments and companies move toward resilience in healthcare supply chains, plant-based platforms are no longer just an alternative — they are becoming a strategic necessity,” said Dr. Elaine Carter, Principal Consultant at Precedence Research.
Segmentation Insights
Product Type Analysis
Therapeutic proteins dominated with 45% share in 2024, owing to their role in treating chronic diseases such as cancer, diabetes, and autoimmune disorders. Plant-based systems provide an affordable, scalable pathway to produce complex proteins with correct folding and post-translational modifications.
Vaccines are the fastest-growing product segment, driven by their potential for pandemic response and cost-effective production, especially in regions with limited vaccine infrastructure.
Plant Type/Expression System
Tobacco-based systems led the market with 40% share due to their proven scalability and established genetic tools. However, leafy crops such as spinach and lettuce are expected to grow the fastest, thanks to their potential in edible biologics and greater consumer acceptance compared to tobacco.
Production Method
Transient expression systems captured 50% market share in 2024, valued for their speed and flexibility in urgent healthcare needs. On the other hand, stable expression systems are growing fastest, offering long-term scalability and sustainable protein production for chronic disease therapies.
End User
Pharmaceutical and biotechnology companies accounted for 55% share, leveraging their R&D capacity and regulatory expertise. Meanwhile, CDMOs are the fastest-growing segment as biopharma players increasingly outsource production to cut costs and accelerate commercialization.
Regional Outlook
North America
North America remains the largest market, driven by robust biotech infrastructure, government funding, and strong demand for innovative biologics. The region’s established regulatory framework fosters innovation while ensuring safety, positioning it as the global leader in molecular farming commercialization.
Asia Pacific
Asia Pacific is the fastest-growing region, supported by expanding healthcare access, government-backed biopharma initiatives, and rising investments in affordable biologics. With high infectious disease prevalence and increasing biotech capacity, the region is becoming a critical hub for both innovation and outsourcing.
Market Challenges
Despite its promise, the plant molecular farming market faces barriers:
-
Regulatory Hurdles: Delays due to stringent GMO and biologics approval processes.
-
High Initial Investments: Substantial capex required for controlled cultivation facilities, gene editing tools, and downstream processing.
-
Fragmented Regulations: Divergent national policies complicate international trade and slow product launches.
Plant Molecular Farming Market Companies
- Medicago Inc.
- Kentucky BioProcessing (KBP)
- Protalix Biotherapeutics
- Icon Genetics GmbH
- PlantForm Corporation
- iBio Inc.
- Ventria Bioscience
- Synthon Biopharmaceuticals
- Fraunhofer IME
- ORF Genetics
- Greenovation Biotech GmbH
- Leaf Expression Systems
- PhytoCellTech
- Biolex Therapeutics
- AgroGenesys
- Caliber Biotherapeutics
- Biocentury Plant Systems
- SemBioSys Genetics
- Explant Biotech
- PlantCell Systems
Case in Point: AI-driven Breakthroughs
In 2025, Finally Foods unveiled an AI-driven platform that enabled potatoes to produce dairy proteins with high efficiency, marking a breakthrough in plant-based dairy alternatives. Similarly, University of Queensland researchers introduced a novel nanoparticle-based mRNA delivery via plant roots, reducing development timelines. These cases highlight how plant molecular farming is moving from concept to commercial reality, with AI playing a catalytic role.
Competitive Landscape and Recent Developments
Leading players in the market include Medicago, Kentucky BioProcessing, Protalix Biotherapeutics, iBio, PlantForm Corporation, Ventria Bioscience, and Moolec Science. The competitive focus is on scaling production, securing regulatory approvals, and building partnerships.
-
Moolec Science received USDA approval in October 2024 for genetically engineered peas producing bovine myoglobin.
-
In April 2024, Moolec secured a U.S. patent for its SPC2 safflower platform, ensuring exclusivity until 2041.
-
In 2025, PoLoPo transitioned from lab-scale to field-scale potato cultivation, capable of producing three tons of functional egg proteins per harvest.
These milestones reflect rapid commercialization momentum, positioning plant molecular farming as a mainstream biomanufacturing solution.
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or Asia Pacific.
You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 804 441 9344
Precedence Research offers exclusive subscription services designed to provide in-depth data and analytics insights. With a subscription, you gain access to a comprehensive suite of statistical resources, market intelligence, and research tools tailored to your business needs. Whether you’re looking for industry trends, competitive analysis, or future market projections, our subscription plans ensure you stay ahead with reliable, up-to-date information.
Browse Our Subscription Plans@ https://www.precedenceresearch.com/get-a-subscription